Europe PCSK9-Targeted Therapy Market Size, Share & Trends Analysis Report By Drug Type / Modality (Monoclonal Antibodies (mAbs) Alirocumab Evolocumab, siRNA-based Therapies Inclisiran, Gene Editing and Other Novel Modalities CRISPR-based approaches Antisense oligonucleotides (ASOs) ), By Indication  (Heterozygous Familial Hypercholesterolemia (HeFH), Atherosclerotic Cardiovascular Disease (ASCVD), Homozygous Familial Hypercholesterolemia (HoFH), Hyperlipidemia (Non-FH) ), By Country (U.K., Germany, France, Spain, Italy, Russia, Nordic, Benelux) and Forecast, 2026-2034

Table of Contents

1. Executive Summary
   1. Introduction
2. Market Introduction
   1. Market Definition
   2. Scope of the Study
   3. Market Structure
3. Research Methodology
   1. Primary Research
   2. Research Methodology
   3. Assumptions & Exclusions
   4. Secondary Data Sources
4. Market Factor Analysis
   1. Value Chain Analysis: Europe PCSK9-Targeted Therapy Market
   2. Porters Five Forces Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitution
      4. Threat of New Entrants
      5. Competitive Rivalry
5. Market Dynamics
   1. Drivers
   2. Restraints
   3. Opportunities
6. Recent Trends Analysis
7. Impact of COVID-19 on Europe PCSK9-Targeted Therapy Market
   1. Pre and Post Covid -19 Market Scenario Analysis
   2. Market Recovery Timeline and Challenge
   3. Measures Taken by Top Players
8. Regulatory Landscape
9. Europe PCSK9-Targeted Therapy Market, By Drug Type / Modality
   1. Introduction
      1. Market Size and Forecast, By Drug Type / Modality
   2. Monoclonal Antibodies (mAbs) 
      1. Market Size and Forecast, By Region
      2. Alirocumab 
         1. Market Size and Forecast, By Region
      3. Evolocumab 
         1. Market Size and Forecast, By Region
   3. siRNA-based Therapies 
      1. Market Size and Forecast, By Region
      2. Inclisiran 
         1. Market Size and Forecast, By Region
   4. Gene Editing and Other Novel Modalities 
      1. Market Size and Forecast, By Region
      2. CRISPR-based approaches 
         1. Market Size and Forecast, By Region
      3. Antisense oligonucleotides (ASOs) 
         1. Market Size and Forecast, By Region
10. Europe PCSK9-Targeted Therapy Market, By Indication 
    1. Introduction
       1. Market Size and Forecast, By Indication 
    2. Heterozygous Familial Hypercholesterolemia (HeFH) 
       1. Market Size and Forecast, By Region
    3. Atherosclerotic Cardiovascular Disease (ASCVD) 
       1. Market Size and Forecast, By Region
    4. Homozygous Familial Hypercholesterolemia (HoFH) 
       1. Market Size and Forecast, By Region
    5. Hyperlipidemia (Non-FH) 
       1. Market Size and Forecast, By Region
11. Europe PCSK9-Targeted Therapy Market, By Route of Administration
    1. Introduction
       1. Market Size and Forecast, By Route of Administration
    2. Subcutaneous Injection 
       1. Market Size and Forecast, By Region
    3. Intravenous Injection 
       1. Market Size and Forecast, By Region
    4. Oral (in pipeline) 
       1. Market Size and Forecast, By Region
12. Europe PCSK9-Targeted Therapy Market, By Distribution Channel
    1. Introduction
       1. Market Size and Forecast, By Distribution Channel
    2. Hospital Pharmacies 
       1. Market Size and Forecast, By Region
    3. Retail Pharmacies 
       1. Market Size and Forecast, By Region
    4. Online Pharmacies 
       1. Market Size and Forecast, By Region
13. Europe PCSK9-Targeted Therapy Market, By Patient Type
    1. Introduction
       1. Market Size and Forecast, By Patient Type
    2. Primary Prevention (High Risk, No History of ASCVD) 
       1. Market Size and Forecast, By Region
    3. Secondary Prevention (With History of ASCVD) 
       1. Market Size and Forecast, By Region
    4. Statin-Intolerant Patients 
       1. Market Size and Forecast, By Region
14. Regional Overview
    1. Introduction
       1. Market Size and Forecast
    2. Europe
       1. Market Size and Forecast
          1. By Drug Type / Modality
             1. Monoclonal Antibodies (mAbs) 
             1. Alirocumab 
             2. Evolocumab 
             2. siRNA-based Therapies 
             1. Inclisiran 
             3. Gene Editing and Other Novel Modalities 
             1. CRISPR-based approaches 
             2. Antisense oligonucleotides (ASOs) 
          2. By Indication 
             1. Heterozygous Familial Hypercholesterolemia (HeFH) 
             2. Atherosclerotic Cardiovascular Disease (ASCVD) 
             3. Homozygous Familial Hypercholesterolemia (HoFH) 
             4. Hyperlipidemia (Non-FH) 
          3. By Route of Administration
             1. Subcutaneous Injection 
             2. Intravenous Injection 
             3. Oral (in pipeline) 
          4. By Distribution Channel
             1. Hospital Pharmacies 
             2. Retail Pharmacies 
             3. Online Pharmacies 
          5. By Patient Type
             1. Primary Prevention (High Risk, No History of ASCVD) 
             2. Secondary Prevention (With History of ASCVD) 
             3. Statin-Intolerant Patients 
       2. United Kingdom
          1. By Drug Type / Modality
             1. Monoclonal Antibodies (mAbs) 
             1. Alirocumab 
             2. Evolocumab 
             2. siRNA-based Therapies 
             1. Inclisiran 
             3. Gene Editing and Other Novel Modalities 
             1. CRISPR-based approaches 
             2. Antisense oligonucleotides (ASOs) 
          2. By Indication 
             1. Heterozygous Familial Hypercholesterolemia (HeFH) 
             2. Atherosclerotic Cardiovascular Disease (ASCVD) 
             3. Homozygous Familial Hypercholesterolemia (HoFH) 
             4. Hyperlipidemia (Non-FH) 
          3. By Route of Administration
             1. Subcutaneous Injection 
             2. Intravenous Injection 
             3. Oral (in pipeline) 
          4. By Distribution Channel
             1. Hospital Pharmacies 
             2. Retail Pharmacies 
             3. Online Pharmacies 
          5. By Patient Type
             1. Primary Prevention (High Risk, No History of ASCVD) 
             2. Secondary Prevention (With History of ASCVD) 
             3. Statin-Intolerant Patients 
       3. Germany
       4. France
       5. Spain
       6. Italy
       7. Russia
       8. Nordic
       9. Benelux
       10. Rest of Europe
15. Competitive Landscape, 2025
    1. Introduction
    2. Europe PCSK9-Targeted Therapy Market Share Analysis, 2025 (%)
       1. Market Share Analysis, 2025
       2. Competition Ranking, 2025
       3. Key Developments & Growth Strategies
          1. Merger & Acquisition
          2. Product Launch
          3. Expansion
       4. Consolidated SWOT Analysis of Key Players
16. Company Profile
    1. Amgen
       1. Business Overview
       2. Financial Data
       3. Key Product domains
       4. Recent Developments
    2. Novartis
    3. Sanofi
    4. Regeneron Pharmaceuticals
    5. Merck & Co.
    6. Eli Lilly and Company
    7. LIB Therapeutics
    8. AstraZeneca
    9. Ionis Pharmaceuticals
    10. Silence Therapeutics
    11. Alnylam Pharmaceuticals
    12. Arrowhead Pharmaceuticals
    13. CRISPR Therapeutics